Valion Bio, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
Our condensed financial statements included in this Quarterly Report on Form 10‑Q are as follows:
| Condensed Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024 | 2 |
|---|---|
| Condensed Statements of Operations for the three months ended March 31, 2025 and 2024 (unaudited) | 3 |
| Condensed Statements of Stockholders’ Equity for the three months ended March 31, 2025 and 2024 (unaudited) | 4 |
| Condensed Statements of Cash Flow for the three months ended March 31, 2025 and 2024 (unaudited) | 5 |
| Notes to Condensed Financial Statements (unaudited) | 6 |
This Quarterly Report on Form 10‑Q (this "Report") for the quarter ended March 31 2025, should be read in conjunction with the Company’s Annual Report on Form 10‑K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 21, 2025.
The accompanying condensed financial statements and footnotes have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10‑Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended March 31, 2025 are not necessarily indicative of the results that can be expected for the full year.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.